Inhibikase Therapeutics Q2 EPS $(0.11), Inline
Inhibikase Therapeutics (NASDAQ: IKT ) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is unchanged from the same period last year.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.